InxMed Unveils New Clinical Data for Ifebemtinib
InxMed Co., Ltd, a pioneering biotech company committed to revolutionizing cancer therapies, has shared significant results from its Phase Ib/II clinical trial evaluating the combination of ifebemtinib (IN10018) and garsorasib, targeting KRAS G12C-mutation solid tumors. This breakthrough was recently presented during a notable meeting.
Overview of Clinical Trial Results
The presented data focuses on a dual approach combining ifebemtinib, an oral focal adhesion kinase (FAK) inhibitor, with garsorasib, a KRAS G12C inhibitor. Both treatments aim to address the challenges posed by KRAS G12C mutations in solid tumors.
Key Findings from the NSCLC Cohort
The first cohort evaluated patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). Remarkably, as of the latest data collection, there was a remarkable objective response rate (ORR) of 90.3%, showcasing the efficacy of the combined treatment. In total, 33 patients were enrolled, and the median follow-up duration extended beyond 16 months, yielding the following outcomes:
- Median progression-free survival (mPFS) of 22.3 months
- Median duration of response (mDOR) of 19.4 months
- Median overall survival (mOS) status yet to be determined but showing a promising survival curve.
This combination proved effective irrespective of PD-L1 expression levels, demonstrating its potential as a reliable treatment option for diverse patient populations.
Results from the Colorectal Cancer Cohort
In the colorectal cancer (CRC) segment of the trial, 36 previously treated patients were divided into two groups: one receiving the combination treatment and the other on garsorasib alone. The results illustrated a clear benefit from adding ifebemtinib:
- ORR reached 44.4% in the combination group compared to 16.7% in the monotherapy group.
- Every patient in the combo group achieved disease control, unlike 77.8% in the mono arm.
- mPFS was reported at 7.7 months versus 4.0 months for monotherapy.
- Notably, the combination arm demonstrated significant early survival advantages.
Feedback from Leadership and Future Directions
Dr. Zaiqi Wang, CEO of InxMed, expressed enthusiasm regarding the trial outcomes, emphasizing the remarkable response rates and extended durations of remission. The data solidifies the role of ifebemtinib in enhancing the effectiveness of KRAS inhibitors, marking a paradigm shift in treating KRAS G12C-driven cancers with a favorable safety profile.
Looking ahead, InxMed is set to initiate a randomized Phase III pivotal trial centered on first-line KRAS G12C-mutant NSCLC treatments. The research indicates the company’s commitment to explore various combinations of ifebemtinib with other KRAS-targeted agents.
Understanding Ifebemtinib (IN10018)
Ifebemtinib is a selective, orally administered small molecule designed to inhibit FAK. Its therapeutic profile suggests significant potential across different modalities, including chemotherapy and immunotherapy, making it a competitive player in cancer treatment development.
With over 600 patients treated to date, ifebemtinib has received accolades for its favorable safety and tolerability. It is recognized with Breakthrough Therapy Designation from the China National Medical Products Administration and Fast-Track Designation from the U.S. FDA.
About InxMed
Founded in 2018, InxMed is at the forefront of cancer treatment innovation, focusing on overcoming challenges related to tumor resistance and metastasis. The company combines insights from tumor biology with advanced translational research, aiming to create novel therapies. With a growing pipeline addressing various cancer types, InxMed stands as a formidable entity in oncology research.
Frequently Asked Questions
What is ifebemtinib?
Ifebemtinib (IN10018) is a selective FAK inhibitor used in treating KRAS G12C-mutant cancers, showing promising results in early trials.
What were the main results from the NSCLC cohort?
The NSCLC cohort exhibited a 90.3% objective response rate and a median progression-free survival of 22.3 months.
How did ifebemtinib perform against monotherapy in CRC patients?
In CRC patients, the combination of ifebemtinib and garsorasib showed a 44.4% response rate, significantly outperforming monotherapy.
What is the future direction for InxMed regarding these treatments?
InxMed plans to initiate a Phase III trial and explore combinations with other KRAS-targeted agents based on promising synergy data.
How can patients participate in future trials?
Interested patients should consult their healthcare providers for potential eligibility in ongoing or future clinical trials with InxMed.
